Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, announced the launch of ClinFAST™, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.
By reducing production timelines while maintaining high-quality standards, ClinFAST addresses a significant challenge faced by drug developers—securing fill/finish capacity in a market where small-batch projects are often deprioritized by larger contract manufacturing organizations (CMOs).